Compare Source Natural with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
INR 85 Cr (Micro Cap)
30.00
32
0.00%
0.01
12.43%
3.68
Total Returns (Price + Dividend) 
Source Natural for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Source Natural Foods & Herbal Supplements Ltd is Rated Strong Sell
Source Natural Foods & Herbal Supplements Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 05 Feb 2026, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 02 March 2026, providing investors with the latest insights into its performance and outlook.
Read full news article
Source Natural Foods & Herbal Supplements Ltd is Rated Strong Sell
Source Natural Foods & Herbal Supplements Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 05 February 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 17 February 2026, providing investors with the latest perspective on the company’s position.
Read full news article
Source Natural Foods Q3 FY26: Revenue Surge Masks Margin Erosion Concerns
Source Natural Foods & Herbal Supplements Ltd., a Bangalore-based pharmaceutical company specialising in organic ayurvedic formulations, reported a mixed bag of results for Q3 FY26, with robust revenue growth overshadowed by persistent margin compression. The micro-cap company posted net profit of ₹0.82 crores for the quarter ended December 2025, representing a sequential increase of 17.14% from Q2 FY26's ₹0.70 crores, though this marked a sharp 19.61% decline from the ₹1.02 crores earned in Q3 FY25.
Read full news article Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
16-Feb-2026 | Source : BSENewspaper Publication for Unaudited Financial Results for the quarter and nine months ended December 31 2025.
Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025
14-Feb-2026 | Source : BSEUnaudited Financial Results for the quarter and nine months ended December 31 2025
Board Meeting Outcome for Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025
14-Feb-2026 | Source : BSEUnaudited Financial Results for the quarter and nine months ended December 31 2025
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 0 FIIs
Sriveda Sattva Private Limited (74.37%)
Guttikonda Vara Lakshmi (2.96%)
18.68%
Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ
QoQ Growth in quarter ended Dec 2025 is 19.76% vs 40.08% in Sep 2025
QoQ Growth in quarter ended Dec 2025 is 17.14% vs 11.11% in Sep 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 57.79% vs 47.63% in Sep 2024
Growth in half year ended Sep 2025 is 5.56% vs 173.91% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 71.00% vs 40.99% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -5.70% vs 60.56% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is 64.54% vs 38.09% in Mar 2024
YoY Growth in year ended Mar 2025 is 66.67% vs -17.92% in Mar 2024






